Not recruiting yet
Post-Market Study of Transbronchial Cryo-assisted RFA During Robotic Bronchoscopy With Subsequent Surgical Resection
NCT07398027 · Carolin Steinack · Updated 9 Feb 2026
- What is being tested
- HybridTherm® System
- For
- Lung Cancer
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 20 people. The full rules are on the registry page.
- Where
- Switzerland
- When
- Starts or started March 2026, ends Sept 2027. Registered 9 Feb 2026.
- Results
- None posted yet.
In the researchers' words
The purpose of this study is to confirm the procedural feasibility and device usability of the HybridTherm® system during bronchoscopic cryo-assisted radiofrequency ablation (RFA) performed prior to scheduled surgical resection in patients with lung cancer. The bronchoscopy session includes tumor ablation and, when clinically indicated, mediastinal lymph node staging by EBUS-TBNA.
Sites
- University Hospital ZurichZurich, Raemistrasse, Switzerland